1 Shendure J, et al. DNA sequencing at 40: past, present and future. Nature. 2017;550(7676):345–53.
2 Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl Med. 2014;370(25):2418–25.
3 Kerem B, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;4922:1073–80.
4 Black DM. Solomon E. The search for the familial breast/ovarian cancer gene. Trends Genet. 1993;9(1):22–6.
5 Visscher PM, et al. 10 Years of GWAS Discovery: Biology, Function, and Translation. Am J Hum Genet. 2017;101(1):5–22.
6 Stein EA, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12):1108–18.
7 Abifadel M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–6.
8 Hooper AJ, et al. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007;193(2):445–8.
9 Lauschke VM, Ingelman-Sundberg M, How to Consider Rare Genetic Variants in Personalized Drug Therapy. Clinical Pharmacology & Therapeutics. 2018;103(5):745–8.
10 Schuck RN, Grillo JA. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling. AAPS J. 2016;18(3):573–7.
11 Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017;19(1):20–9.
12 Wartman LD. A case of me: clinical cancer sequencing and the future of precision medicine. Cold Spring Harb Mol Case Stud. 2015;1(19:a000349.
13 Erlich Y, Zielinski D. DNA Fountain enables a robust and efficient storage architecture. Science. 2017;355(6328):950–4.
14 Monegain B. Microsoft, Google invest in precision medicine startup DNAnexus. 2018 [cited 2018 27 Aug]; Available from:
https://www.healthcareitnews.com/news/microsoft-google-invest-precision-medicine-startup-dnanexus.